Cargando…

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania

Long acting injectable antipsychotics (LAIs) are considered the ideal treatment for schizophrenia, especially for young patients with high rates of non-adherence. In the current COVID-19 pandemic, it has been reported that the administration of LAIs decreased in some areas. The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Miron, Ana A., Ifteni, Petru I., Teodorescu, Andreea, Petric, Paula S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316377/
https://www.ncbi.nlm.nih.gov/pubmed/35885792
http://dx.doi.org/10.3390/healthcare10071265
_version_ 1784754799383674880
author Miron, Ana A.
Ifteni, Petru I.
Teodorescu, Andreea
Petric, Paula S.
author_facet Miron, Ana A.
Ifteni, Petru I.
Teodorescu, Andreea
Petric, Paula S.
author_sort Miron, Ana A.
collection PubMed
description Long acting injectable antipsychotics (LAIs) are considered the ideal treatment for schizophrenia, especially for young patients with high rates of non-adherence. In the current COVID-19 pandemic, it has been reported that the administration of LAIs decreased in some areas. The aim of this study was to evaluate the impact of COVID-19 pandemic on the initiation of LAIs. This is a retrospective mirror- image study covering a total period of 24 months: 12 months before and 12 months after the declaration of COVID-19 pandemic on March 11, 2020. During the study period, out of 218 patients admitted with schizophrenia, only 15 (1.3%) received LAIs at discharge. There was a 48.3% reduction in LAIs initiation compared to the pre-pandemic period (29 LAIs initiations in 2019 from 224 admissions). Despite the 27% reduction in the total number of admissions (1500 in 2019 vs. 1100 in 2020), the number of admissions with schizophrenia remained almost the same (224 in 2019 vs. 218 in 2020). COVID-19 pandemic brought an important challenge in the treatment of patients with schizophrenia, especially in the initiation of LAIs. This could have an important impact on the relapse rate in the next period.
format Online
Article
Text
id pubmed-9316377
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93163772022-07-27 Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania Miron, Ana A. Ifteni, Petru I. Teodorescu, Andreea Petric, Paula S. Healthcare (Basel) Article Long acting injectable antipsychotics (LAIs) are considered the ideal treatment for schizophrenia, especially for young patients with high rates of non-adherence. In the current COVID-19 pandemic, it has been reported that the administration of LAIs decreased in some areas. The aim of this study was to evaluate the impact of COVID-19 pandemic on the initiation of LAIs. This is a retrospective mirror- image study covering a total period of 24 months: 12 months before and 12 months after the declaration of COVID-19 pandemic on March 11, 2020. During the study period, out of 218 patients admitted with schizophrenia, only 15 (1.3%) received LAIs at discharge. There was a 48.3% reduction in LAIs initiation compared to the pre-pandemic period (29 LAIs initiations in 2019 from 224 admissions). Despite the 27% reduction in the total number of admissions (1500 in 2019 vs. 1100 in 2020), the number of admissions with schizophrenia remained almost the same (224 in 2019 vs. 218 in 2020). COVID-19 pandemic brought an important challenge in the treatment of patients with schizophrenia, especially in the initiation of LAIs. This could have an important impact on the relapse rate in the next period. MDPI 2022-07-07 /pmc/articles/PMC9316377/ /pubmed/35885792 http://dx.doi.org/10.3390/healthcare10071265 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Miron, Ana A.
Ifteni, Petru I.
Teodorescu, Andreea
Petric, Paula S.
Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
title Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
title_full Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
title_fullStr Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
title_full_unstemmed Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
title_short Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
title_sort long-acting injectable antipsychotics (lais) prescribing trends during the covid-19 pandemic in romania
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316377/
https://www.ncbi.nlm.nih.gov/pubmed/35885792
http://dx.doi.org/10.3390/healthcare10071265
work_keys_str_mv AT mironanaa longactinginjectableantipsychoticslaisprescribingtrendsduringthecovid19pandemicinromania
AT iftenipetrui longactinginjectableantipsychoticslaisprescribingtrendsduringthecovid19pandemicinromania
AT teodorescuandreea longactinginjectableantipsychoticslaisprescribingtrendsduringthecovid19pandemicinromania
AT petricpaulas longactinginjectableantipsychoticslaisprescribingtrendsduringthecovid19pandemicinromania